AlphaMbeta2 integrin modulator exerts antitumor activity in vivo

Juho Suojanen1, Tuula Salo, Timo Sorsa

  • 1Department of Oral and Maxillofacial Diseases, Helsinki University Central Hospital, Institute of Dentistry, University of Helsinki, FI-00014, Finland. juho.suojanen@helsinki.fi

Anticancer Research
|January 30, 2008
PubMed
Summary

The novel small molecule IMB-10 effectively targets leukocyte alphaMbeta2 integrin, inhibiting the growth of lymphoma and leukemia xenografts. This immunomodulatory therapy also reduced tumor-infiltrating leukocytes and impacted squamous cell carcinoma invasion.